Short answer
Edgewise Therapeutics, Inc. (EWTX) filed an 8-K current report with the SEC on July 16, 2026 reporting Item EX-99.1 (Exhibit EX-99.1). Servier transaction produced $1.55B upfront cash and up to $1.1B milestones, transforming Edgewise into a cardiovascular-focused company.
Edgewise Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item EX-99.1 · Exhibit EX-99.1
- Servier transaction produced $1.55B upfront cash and up to $1.1B milestones, transforming Edgewise into a cardiovascular-focused company
- Pro forma cash and equivalents rose to $1.532B, with total assets reaching $2.014B and stockholders’ equity $1.755B
- Estimated after-tax gain of $1.262B, partially offset by $50M transaction costs and $225.856M income taxes
- Divestiture removes $75.544M of annualized 2025 operating expenses, including $69.821M R&D and $5.723M G&A
- Milestones excluded from recognized gain, while an 18-month minimum transition-services agreement creates $17.880M deferred income
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Edgewise Therapeutics, Inc. 8-K filings
Get the next EWTX 8-K as it lands
Follow EWTX for push alerts, or ask the research agent what this filing means.